Last reviewed · How we verify
Placebo Matched to Low-Dose Cannabidiol
Placebo Matched to Low-Dose Cannabidiol is a Cannabinoid Small molecule drug developed by Wayne State University. It is currently in Phase 3 development for Indication under investigation in Phase 3 trial (specific indication not specified in provided information).
Cannabidiol (CBD) modulates endocannabinoid signaling and multiple receptor systems to produce therapeutic effects.
Cannabidiol (CBD) modulates endocannabinoid signaling and multiple receptor systems to produce therapeutic effects. Used for Indication under investigation in Phase 3 trial (specific indication not specified in provided information).
At a glance
| Generic name | Placebo Matched to Low-Dose Cannabidiol |
|---|---|
| Sponsor | Wayne State University |
| Drug class | Cannabinoid |
| Target | CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor |
| Modality | Small molecule |
| Therapeutic area | Neurology |
| Phase | Phase 3 |
Mechanism of action
CBD is a non-intoxicating cannabinoid that interacts with CB1 and CB2 receptors, serotonin receptors (5-HT1A), vanilloid receptors (TRPV1), and other targets to exert anti-inflammatory, anxiolytic, and neuroprotective effects. The exact mechanism varies by indication but generally involves modulation of neurotransmitter systems and reduction of neuroinflammation.
Approved indications
- Indication under investigation in Phase 3 trial (specific indication not specified in provided information)
Common side effects
- Fatigue
- Diarrhea
- Changes in appetite
- Somnolence
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Placebo Matched to Low-Dose Cannabidiol CI brief — competitive landscape report
- Placebo Matched to Low-Dose Cannabidiol updates RSS · CI watch RSS
- Wayne State University portfolio CI
Frequently asked questions about Placebo Matched to Low-Dose Cannabidiol
What is Placebo Matched to Low-Dose Cannabidiol?
How does Placebo Matched to Low-Dose Cannabidiol work?
What is Placebo Matched to Low-Dose Cannabidiol used for?
Who makes Placebo Matched to Low-Dose Cannabidiol?
What drug class is Placebo Matched to Low-Dose Cannabidiol in?
What development phase is Placebo Matched to Low-Dose Cannabidiol in?
What are the side effects of Placebo Matched to Low-Dose Cannabidiol?
What does Placebo Matched to Low-Dose Cannabidiol target?
Related
- Drug class: All Cannabinoid drugs
- Target: All drugs targeting CB1 receptor, CB2 receptor, 5-HT1A receptor, TRPV1 receptor
- Manufacturer: Wayne State University — full pipeline
- Therapeutic area: All drugs in Neurology
- Indication: Drugs for Indication under investigation in Phase 3 trial (specific indication not specified in provided information)
- Compare: Placebo Matched to Low-Dose Cannabidiol vs similar drugs
- Pricing: Placebo Matched to Low-Dose Cannabidiol cost, discount & access